Skip to main content

Haemophilia A

Decorative illustration

How is Roche improving treatment for haemophilia A?

We are consistently pushing scientific research to change the lives of those affected by haemophilia A. We strive to deliver a new reality where more people can live life with a mind free from haemophilia A.

What is haemophilia A?

Haemophilia A, the most well-known inherited bleeding disorder,  is a serious, inherited bleeding disorder in which a person’s blood does not clot properly, in severe cases leading to uncontrolled bleeding, either spontaneously or after minor trauma.

What are the challenges faced by people living with haemophilia A?

It is so much more than a diagnosis – living with haemophilia A is a daily reality where school and work are missed, plans are cancelled and entire families feel its effect. It's a worry that carries across generations, for life, often right from the day a person with haemophilia A is born.   

We believe that even one bleed is one too many, especially in a condition like haemophilia A that is for life. 

How is Roche improving outcomes for people living with haemophilia A?

For decades, people with haemophilia A have relied on frequent intravenous infusions - where medicine is delivered directly into a vein - often multiple times a week, just to manage their condition. We set out to change this. Nearly ten years ago, we transformed the way haemophilia A is treated, and changed the future of many people already living and being born with haemophilia A. Today, a child born with haemophilia A can start their life on preventative treatment (prophylaxis) from day one and have a very different outlook to that of their grandparent.  

We have not stopped there and continue to raise the bar and redefine standards of care for patients now, and for generations to come. Our aspiration is that one day we’ll find and deliver a cure for haemophilia A. 

We are proud to be part of the transformation of haemophilia A care, made possible through partnering with the amazingly dedicated community. Our long term support goes beyond research and drug development, working alongside the community with a shared vision to advance the management and care of those with haemophilia A. 

By partnering with patient groups and policy makers, such as the World Federation of Hemophilia, we are committed to make it easier for people to have access to haemophilia A treatment and care. With the community's support, we continue our vision for a new reality so that many more people can live life with a mind free from haemophilia A.

Downloads

Decorative illustration

Download What is haemophilia A?

Haemophilia A is the most common form of haemophilia, a rare inherited bleeding disorder in which low levels of clotting factor VIII prevent the blood from clotting properly. Explore this infographic to learn about haemophilia A, including its causes, symptoms, severity levels and approaches to treatment and bleed prevention.

PDF

Decorative illustration

Download Disease severity in haemophilia A

Haemophilia A is classified as mild, moderate or severe based on the amount of clotting factor VIII in the blood, but disease severity does not always predict a person's bleeding experience or overall burden. Explore this infographic to learn how haemophilia A severity is defined and why every bleed matters, regardless of severity.

PDF

Decorative illustration

Download WFH Guidelines

The World Federation of Hemophilia (WFH) Guidelines highlight how advances in haemophilia A care are reshaping treatment goals, with a greater focus on sustained bleed prevention, quality of life and individualized care. Explore this infographic to learn how evolving standards of care and innovative therapies are helping to expand treatment options for people with haemophilia A.

PDF

Stories of

Haemophilia

See more stories

Discover more

Partnering

Innovation

At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.

Clinical trials

Innovation

Clinical trials are essential to determine whether new drugs or diagnostics are safe and effective when used to diagnose or treat people.